It's been a while since I posted, so I thought I'd share my recent blood work and other updates. Health-wise, things have been good overall, but I continue to have days where I feel completely drained—like a zombie has sucked all the energy out of me. The fatigue hits especially hard mid-day. Still working on solutions on this issue.
Last week, I had my annual telehealth visit with Dr. Gotlib at Stanford. My questions focused on doing everything I can to hopefully halt any progression and learning about the latest drugs and research developments.
Over the past few months, my hematocrit has been below normal at 34.7% (with no phlebotomies for two years + ), and my WBC is still low 3.4. Given these trends, Dr. Gotlib advised lowering my Besremi dose to either 150 mg every three weeks or titrating down to 100 mg every two weeks. My regular hematologist and I had discussed lowering the Besremi dose previously, but I was hesitant because I liked how much my Jak2 levels had been falling. However, given Dr. Gotlib's advice, I’m now at 100 mg every two weeks—and I hope my Jak2 continues to drop.
I asked him about the importance of lowering the JAK2 mutation and the potential advantages of doing so to hopefully stop progression, even though the research isn’t definitive. He seemed very positive about the importance of lowering JAK2 levels, explaining that Besremi works by targeting and killing the JAK2 mutation cells--a good thing.
Since started Besremi in early 2023 my JAK2 has gone from 51.89% to 13.17%
I hadn’t realized that drops in hematocrit and WBC could potentially indicate progression to myelofibrosis. I’m hopeful that these numbers will start to climb after reducing my Besremi dose.